Frontage, a full service contract research organization (CRO), has named Michael Willett, PharmD., RAC, as president of its clinical business unit. Dr. Willett is a seasoned industry professional with more than 25 years of experience in clinical research involving new chemical entities, biologics, biosimilars, medicines targeted for new therapeutic uses (505(b)(2) programs), consumer health, and generic drugs. In 1994, Dr. Willett established Advanced Biomedical Research Inc. (ABR), a Phase I...